SEATTLE, Sept. 17 /PRNewswire/ -- VLST Corp, a Seattle-based
biotechnology company focused on the development of therapeutics for
autoimmune and inflammatory disorders, today announced the appointments of
Consuelo M. Blosch, M.D. as Vice President of Clinical and Regulatory and
Dan Allison, Ph.D, as Senior Director of Therapeutic Design.
Blosch joins VLST from the Benaroya Research Institute at Virginia
Mason (BRI), where she served as administrative director of the BRI
Clinical Research Program. There, she provided leadership oversight to
investigators involved in more than 200 clinical trials. Prior to BRI,
Blosch held director level positions at Immunex Corporation and NPS
Pharmaceuticals, Inc. At Immunex, where she worked from 1992 to 1998,
Blosch directed the soluble receptor program, participating in the study
design and overseeing the monitoring for clinical trials including those
for ENBREL. At NPS, she directed a global research program for a
recombinant human parathyroid hormone for the treatment of osteoporosis.
Blosch received an M.D. from the University of Massachusetts Medical
Allison joins VLST from ICOS Corporation, where he worked from 1992 to
2007, and most recently served as Senior Director, Production Development.
At ICOS, Allison was responsible for engineering antibodies and other
proteins used in clinical studies and also directed the development of
microbial and mammalian expression systems used to produce those proteins.
Prior to ICOS, Allison worked at Genencor International. Allison received a
Ph.D. from the Genetics Department at the University of Washington and
carried out post- doctoral studies in yeast cell biology at the Biozentrum
in Basel, Switzerland and in the Biochemistry Department at the University
"Consuelo's vast experience in the implementation, direction and design
of clinical trials will be truly invaluable to VLST as we begin to advance
our novel product candidates toward clinical development," said Martin
Simonetti, President and Chief Executive Officer of VLST. "In addition, Dan
brings significant protein engineering expertise that will guide the design
of our therapeutic candidates. We are pleased to have such talented
individuals join our team and look forward to their contributions."
VLST Corporation is a privately held biotechnology company dedicated to
the streamlined discovery and development of novel therapeutics for the
treatment of inflammatory and autoimmune disorders. The VLST approach
combines novel bioinformatics and cutting-edge proteomics to provide a
rapid and rational approach to identifying new targets for the development
of novel biologic therapies. The process used to identify clinically
relevant targets also provides a path to developing biologic molecules that
can be used for target validation studies. Such an approach offers the
opportunity to improve the prioritization of product candidates and reduce
costs by improving the clinical success rate. The VLST discovery platform
has primary applications for the treatment of rheumatoid arthritis, Crohn's
disease, multiple sclerosis, lupus and diabetes. For more information,
please visit http://www.vlstcorp.com.
SOURCE VLST Corporation